Avedro, Inc. recently announced it had received approval from the U.S. Food and Drug Administration (FDA) for Photrexa® Viscous, Photrexa® and the KXL® System used in corneal collagen cross-linking for the treatment of corneal ectasia following refractive surgery — the products' second indication.
As we reported back in April, Avedro received FDA approval for photoenhancers, Photrexa Viscous and Photrexa, used in conjunction with the KXL System, for the treatment of progressive keratoconus.
Click here to read the full press release.